This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
Questions about our CME?
Questions about our CME?

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Updates in Precision Medicine: Elevating the Treatment of Severe, Eosinophilic Asthma

Updates in Precision Medicine: Elevating the Treatment of Severe, Eosinophilic Asthma

Format

Webcast

Time to Complete

1.50 hours

Released

December 15, 2018

Expires

December 15, 2019
Add to Queue


Maximum Credits

1.50 / AMA PRA Category 1 CreditsTM

Accredited Provider

Provided by the Annenberg Center for Health Sciences at Eisenhower

Commercial Supporter

This activity is supported by educational grants from AstraZeneca and GlaxoSmithKline.

Program Description

Approximately 12 million children and adults in the U.S. have inadequately controlled asthma, many with severe asthma. Reynold Panettieri, Jr., MD and Nicola Hanania, MD, MS, discuss the importance of and how to differentiate severe from uncontrolled asthma.

Content Areas: Definition and features, GINA 2018, Pathophysiology, Phenotypes and biomarkers, Shared decision-making, and Targeted biologics

Intended Audience

This activity was developed for pulmonologists, allergists, and other clinicians involved in the management of severe asthma.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Describe current evidence for the use of biological-based therapies for the treatment of severe asthma
  • Differentiate biological-based therapies for the treatment of severe asthma based on patient- and treatment-related factors
  • Utilize genetic information to select the appropriate biological-based therapy for a patient with severe asthma
  • Apply updated guidance to optimally utilize biological-based therapy in patients with severe asthma

Conflict Of Interest Disclosure Policy

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Faculty

Nicola A. Hanania, MD, MS
Associate Professor of Medicine
Section of Pulmonary and Critical Care Medicine
Director, American Lung Association Airways Clinical Research Center
Baylor College of Medicine
Houston, Texas

Dr. Hanania discloses the following:
Research Support: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline
Consultant: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi/Regeneron
Speaker Bureau: AstraZeneca

Reynold A. Panettieri, Jr, MD
Vice Chancellor for Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Robert Wood Johnson Medical School
New Brunswick, New Jersey

Dr. Panettieri discloses the following:
Research Support: AstraZeneca, Bristol-Myers Squibb, Genentech, Gilead, MedImmune, Oncoarendi, RFIM, Sanofi/Regeneron, Theratrophix, Vertex
Consultant: AstraZeneca, Boehringer Ingelheim, MedImmune, Novartis
Speaker Bureau: AstraZeneca, Boehringer Ingelheim, MedImmune, Sanofi/Regeneron, Teva

Publishing Staff Disclosures

Additional content planners
Eugene Cullen, MD (peer reviewer) has nothing to disclose.
Gregory Scott, PharmD, RPh (lead nurse planner) has nothing to disclose.

Annenberg Center for Health Sciences
Charles Willis
, Director of Continuing Education, consults for Pfizer, Inc.

All the staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Credit

1.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.

Disclaimer

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Instructions

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the material, reflecting on its implications for your practice, and completing the assessment component.

Please note: The content of this activity is housed on the website of our educational partner, Annenberg Center for Health Sciences at Eisenhower, and requires you to leave myCME and register on the Annenberg website.

Your certificate will be saved on the Annenberg website only and cannot be accessed in your myCME CME History. Please go to https://education.annenberg.net and sign in to access your certificate in the future.

Contact Information

For help or questions about this Internet activity, please contact Annenberg Continuing Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone: 760-773-4500
Fax: 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday

Privacy Policy

Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us, or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at http://www.annenberg.net/privacy-policy/

myCME privacy policy
Add to Queue